Literature DB >> 12950678

Histamine inhibits neutrophil NADPH oxidase activity triggered by the lipoxin A4 receptor-specific peptide agonist Trp-Lys-Tyr-Met-Val-Met.

A Betten1, C Dahlgren, S Hermodsson, K Hellstrand.   

Abstract

The vasoactive amine histamine is found at high concentrations in the immune and inflammatory tissues. Earlier studies have revealed that histamine regulates the nicotinamide-adenine dinucleotide phosphate (NADPH) oxidase-dependent formation of oxygen radicals by phagocytic cells. However, the effects of histamine on intracellular signal transduction mechanisms of relevance to oxidase regulation remain controversial. For this study, we investigated the effects of histamine on NADPH oxidase activity in human neutrophil granulocytes triggered by a lipoxin A4 receptor agonist [the hexapeptide Trp-Lys-Tyr-Met-Val-Met (WKYMVM), a formyl peptide receptor (FPR) agonist (the chemotactic tripeptide formylmethionyl-leucyl-phenylalanine (fMLF)) and an activator of protein kinase C (phorbol myristate acetate (PMA)]. We report that histamine, acting via H2-type histamine receptors (H2R), suppresses NADPH oxidase-dependent formation of oxygen radicals induced by WKYMVM and fMLF but not that induced by PMA. Peptide-induced mobilization of granule-localized complement receptor 3 (CR3) was unaffected by histamine suggesting that the inhibition specifically affected NADPH oxidase activation. Our data suggest that histamine downregulates FPRL1- and FPR-induced NADPH oxidase activity upstream of protein kinase C (PKC) and downstream of the separation of the peptide-induced signal into granule secretion and oxidase activation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12950678     DOI: 10.1046/j.1365-3083.2003.01301.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  9 in total

1.  The mechanism for activation of the neutrophil NADPH-oxidase by the peptides formyl-Met-Leu-Phe and Trp-Lys-Tyr-Met-Val-Met differs from that for interleukin-8.

Authors:  Huamei Fu; Johan Bylund; Anna Karlsson; Sara Pellmé; Claes Dahlgren
Journal:  Immunology       Date:  2004-06       Impact factor: 7.397

2.  Cyclosporin H, Boc-MLF and Boc-FLFLF are antagonists that preferentially inhibit activity triggered through the formyl peptide receptor.

Authors:  Anna-Lena Stenfeldt; Jennie Karlsson; Christine Wennerås; Johan Bylund; Huamei Fu; Claes Dahlgren
Journal:  Inflammation       Date:  2007-08-09       Impact factor: 4.092

3.  The two neutrophil members of the formylpeptide receptor family activate the NADPH-oxidase through signals that differ in sensitivity to a gelsolin derived phosphoinositide-binding peptide.

Authors:  Huamei Fu; Lena Björkman; Paul Janmey; Anna Karlsson; Jennie Karlsson; Charlotta Movitz; Claes Dahlgren
Journal:  BMC Cell Biol       Date:  2004-12-29       Impact factor: 4.241

4.  Monocytes and neutrophils as 'bad guys' for the outcome of interleukin-2 with and without histamine in metastatic renal cell carcinoma--results from a randomised phase II trial.

Authors:  F Donskov; M Hokland; N Marcussen; H H Torp Madsen; H von der Maase
Journal:  Br J Cancer       Date:  2006-01-30       Impact factor: 7.640

5.  NOX2 inhibition reduces oxidative stress and prolongs survival in murine KRAS-induced myeloproliferative disease.

Authors:  Ebru Aydin; Alexander Hallner; Hanna Grauers Wiktorin; Anna Staffas; Kristoffer Hellstrand; Anna Martner
Journal:  Oncogene       Date:  2018-10-15       Impact factor: 9.867

Review 6.  Mast Cells and Natural Killer Cells-A Potentially Critical Interaction.

Authors:  Liliana Portales-Cervantes; Bassel Dawod; Jean S Marshall
Journal:  Viruses       Date:  2019-06-04       Impact factor: 5.048

7.  Anti-Leukemic Properties of Histamine in Monocytic Leukemia: The Role of NOX2.

Authors:  Roberta Kiffin; Hanna Grauers Wiktorin; Malin S Nilsson; Johan Aurelius; Ebru Aydin; Brianna Lenox; Jonas A Nilsson; Anders Ståhlberg; Fredrik B Thorén; Kristoffer Hellstrand; Anna Martner
Journal:  Front Oncol       Date:  2018-06-18       Impact factor: 6.244

Review 8.  Histamine in cancer immunology and immunotherapy. Current status and new perspectives.

Authors:  María de la Paz Sarasola; Mónica A Táquez Delgado; Melisa B Nicoud; Vanina A Medina
Journal:  Pharmacol Res Perspect       Date:  2021-10

9.  Maintenance therapy with histamine plus IL-2 induces a striking expansion of two CD56bright NK cell subpopulations in patients with acute myeloid leukemia and supports their activation.

Authors:  Angélica Cuapio; Mirte Post; Sabine Cerny-Reiterer; Karoline V Gleixner; Gabriele Stefanzl; Jose Basilio; Susanne Herndlhofer; Wolfgang R Sperr; Nicolaas H C Brons; Emilio Casanova; Jacques Zimmer; Peter Valent; Erhard Hofer
Journal:  Oncotarget       Date:  2016-07-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.